Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) EBT Margin (2016 - 2025)

Wave Life Sciences' EBT Margin history spans 11 years, with the latest figure at 580.17% for Q2 2025.

  • For Q2 2025, EBT Margin fell 41298.0% year-over-year to 580.17%; the TTM value through Dec 2025 reached 1143.44%, down 110157.0%, while the annual FY2025 figure was 478.33%, 38876.0% down from the prior year.
  • EBT Margin reached 580.17% in Q2 2025 per WVE's latest filing, down from 510.93% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 14.66% in Q4 2024 to a low of 13685.61% in Q3 2022.
  • Average EBT Margin over 5 years is 1885.77%, with a median of 189.58% recorded in 2023.
  • Peak YoY movement for EBT Margin: crashed -1366851bps in 2022, then soared 1369897bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 44.92% in 2021, then dropped by -18bps to 52.99% in 2022, then skyrocketed by 76bps to 12.68% in 2023, then skyrocketed by 216bps to 14.66% in 2024, then crashed by -4057bps to 580.17% in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBT Margin are 580.17% (Q2 2025), 510.93% (Q1 2025), and 14.66% (Q4 2024).